Ryan White Care Hepatitis C & B Language
NATAP Webinar:
Friday 12:30pm ET - June 5th, 2026
Register:
Heart Health & HIV Prevention & Care in 2026 & Beyond
Watch Previous NATAP Webinars
Booklet:
ACHIEVING HEALTHY AGING Improving Health Outcomes Over 50
Current HIV Articles and News Updates
HIV
Proof-of-Concept Phase 2a Trial of VH4524184 (VH-184), an Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile
- (06/12/26)
GILEAD AND MERCK ANNOUNCE POSITIVE TOPLINE RESULTS FROM TWO PHASE 3 STUDIES EVALUATING ISLATRAVIR/LENACAPAVIR, AN ORAL ONCE-WEEKLY HIV TREATMENT
- (06/08/26)
Markers of immune function (cd4, viral load) and survival among cancer patients with HIV in the United States: a population-based registry linkage study
- (06/01/26)
More HIV Articles...
Hepatitis D
HEPATITIS D INFECTION: who should be screened AASLD 2018 HBV Guidelines
EASL:
- (06/13/26)
- (06/13/26)
EASL:
Safety, Pharmacokinetics, and Pharmacodynamic Activity of ABI-6250, a First-in-Class Oral Hepatitis D Virus Entry Inhibitor in Healthy Subjects: Interim Results From a Randomized, Blinded, Phase 1a Study
- (06/13/26)
EASL:
Virological breakthroughs during long-term Bulevirtide monotherapy in patients with CHD: integrated analysis from the multicenter real-life save-d and d-shield studies
- (06/12/26)
EASL:
24-Week Safety and Efficacy of Brelovitug Monotherapy for the Treatment of Chronic Hepatitis D: Data From Phase 2b of AZURE-1
- (06/08/26)
More Hep D Articles...
Aging & Perinatally Acquired HIV
EASL:
Senolytics dasatinib and quercetin reduce fibrosis in metabolic dysfunction-associated steatohepatitis: The Truth Study
- (06/12/26)
More Aging & HIV Articles...
PrEP
Preferences for PrEP program attributes among Black women across the Southern United States: A discrete choice experiment
- (05/26/26)
Towards More Accessible and More Inclusive PrEP to Break the Cycle of HIV in France
- (05/19/26)
Expanding PrEP Access Through Decentralized Delivery Models
- (05/18/26)
More PreP Articles...
Current Hepatitis C and B Articles
Hepatitis C
EASL:
Bemnifosbuvir and ruzasvir administered as a fixed-dose combination has low potential to inhibit P-gp, BCRP or OATP1B1/3 mediated transport
- (06/10/26)
More Hep C Articles...
Hepatitis B
HBV Patient Declaration of Rights
-
EASL:
The potentially best-in-class HBV ASO ALG-170674 demonstrates additive to synergistic antiviral activities when combined with other anti-HBV modalities
- (06/14/26)
EASL:
AASLD-EASL Zone ALT Associated with Higher Risk of HCC and Liver-Related Mortality in Chronic Hepatitis B Patients
- (06/14/26)
EASL:
Sustained reduction of HBV antigen levels at ≥6 months follow-up in HBeAg-positive participants with chronic hepatitis B infection after 96 weeks of 300 mg pevifoscorvir sodium monotherapy
- (06/14/26)
EASL:
PEVIFOSCORVIR SODIUM DEMONSTRATES PROFOUND ANTIVIRAL ACTIVITY IN UNTREATED HBeAg POSITIVE SUBJECTS, REGARDLESS OF BASELINE ALT LEVEL
- (06/14/26)
EASL:
Potent and durable off-treatment reduction of HBsAg levels and cccDNA-derived transcripts by the CAM-E ALG-001075 in cellbased experiment
- (06/14/26)
EASL:
Factors Associated With Lack of Alanine Aminotransferase Normalisation in Patients With Chronic Hepatitis B Virus After 8 Years of Tenofovir-Based Treatment
- (06/14/26)
EASL:
Transcriptomic Profiling Reveals Distinct Immune Signatures in Chronic Hepatitis B and Identifies Blood Transcriptional Modules Associated With Hepatitis B e Antigen Loss Following Therapeutic Vaccination With GS-2829 and GS-6779
- (06/14/26)
EASL:
Baseline and On-Treatment Characteristics of HBeAg-Positive Patients and Correlates of HBeAg Loss Following GS-2829 and GS-6779 Therapeutic Vaccination in Virally Suppressed Patients With Chronic Hepatitis B
- (06/14/26)
EASL:
Sequential Combination of Antisense Oligonucleotide AHB-137 Followed by HBV Vaccine Leads to HBsAg Loss and Seroconversion in the AAV-HBV Mice
- (06/14/26)
EASL:
Synergistic Effect of Diabetes and Hypertension on the Risk of Liver Disease Progression in Hepatitis B Virus Infection
- (06/14/26)
EASL:
Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
- (06/14/26)
More Hep B Articles...
Fatty Liver, NAFLD, NASH, MASLD, MASH
EASL:
Machine Learning Models of Non-invasive Tests to Predict MASH and Fibrosis Stage Based on MAESTRO-NAFLD-1 and MAESTRO-NASH Liver Biopsies
- (06/11/26)
EASL:
In F0-F1 and F2-F3 MASH, ≥ 5% weight loss significantly lowers VCTE and ELFTM independent of biopsy fibrosis improvement; resmetirom and not placebo reduction of ELF and VCTE are associated with biopsy improvement of fibrosis, independent of weight loss
- (06/11/26)
EASL:
Baseline ANTICIPATE score and response predicts liver outcome events in a 180 patient MASH cirrhosis cohort treated with resmetirom
- (06/11/26)
EASL:
Early and Week 52 biomarker (MRI-PDFF, ALT, MRE and PRO-C3) responses to resmetirom predict improvements in MASH and liver fibrosis
- (06/11/26)
EASL:
Reducing CV risk in patients with MASH independent of baseline statin use: Lp(a) and LDL-C lowering by resmetirom
- (06/11/26)
EASL:
Dissecting the alternate mediterranean diet score identifies whole grains and red meat as key determinants of fibrosis risk in MASLD...'red/processed meat increased of significant & advanced fibrosis'
- (06/11/26)
More Fatty Liver Articles...
Check Out Our Special NATAP Features
List not necessarily listed here in order of date being held.
Conference List Here
https://www.croiconference.org/
https://academicmedicaleducation.com/programs/3rd-african-workshop-on-women-and-hiv-2026
https://academicmedicaleducation.com/programs/16th-international-workshop-on-women-and-hiv-2026
https://acthiv.org/
https://ddw.org/?doing_wp_cron=1768748258.8390960693359375000000
https://www.easlcongress.eu/
https://asm.org/events/asm-microbe/home
https://academicmedicaleducation.com/programs/24th-european-meeting-on-hiv-and-hepatitis-2026
https://www.iasociety.org/conferences/aids2026
https://academicmedicaleducation.com/programs?page=2
https://academicmedicaleducation.com/programs/27th-international-workshop-on-clinical-pharmacology-of-hiv-hepatitis-and-other-antiviral-drugs-2026
2026 U.S. Conference on HIV/AIDS
Register to join us from September 17-20, 2026 in Anaheim, CA
Theme - United and Unbreakable: The HIV Movement at 45
https://www.nmac.org/uscha/
https://academicmedicaleducation.com/programs/9th-conference-on-liver-disease-in-africa-colda-2026
https://academicmedicaleducation.com/programs/17th-international-workshop-on-aging-and-hiv-2026
https://idweek.org/
https://aasld-igh.org/Home.aspx https://www.aasld.org/the-liver-meeting
https://hivglasgow.org/
